How does DXCM's earnings performance compare to forecasts this year?

DexCom's (DXCM) earnings performance has shown some discrepancies with forecasts this year: 1. **Revenue Comparison**: DexCom's revenue for the fourth quarter (Q4) of 2024 exceeded estimates, with the company reporting $1.114 billion in Q4 2024, surpassing the estimated $1.103 billion. This marks an 8% year-over-year increase. However, no specific estimates were found for the full year's revenue in this year's report, only a forecast for the upcoming year. 2. **Earnings Comparison**: DexCom's fourth-quarter earnings per share (EPS) fell short of analyst expectations, with the company reporting GAAP EPS of $0.38, missing the estimated $0.49. However, non-GAAP EPS was $0.45, which is closer to the estimate. This represents a significant decrease from the previous year's EPS of $0.50. 3. **Year-Over-Year Comparison**: DexCom's full-year revenue for 2024 grew by 11% to $4.03 billion, with U.S. revenue increasing by 10% and international revenue rising by 15%. This indicates a strong overall performance, albeit with some quarterly fluctuations. In conclusion, while DexCom has shown strong revenue growth and surpassed estimates in certain quarters, its earnings have fallen short of forecasts, particularly in the most recent quarter. The company's performance for the full year appears robust, with significant year-over-year growth, despite the recent earnings miss.